Advance in Tumorigenesis Research and Cancer Cell Therapy

Dear Colleagues,

Cancer is still the leading cause of human disease-related death worldwide. Although the application of molecular targeting therapy and immune checkpoint inhibitors has greatly improved patients’ outcome, the five-year overall survival rate is still unsatisfactory for patients with cancer. Hence, there is an urgent need to better understand the molecular mechanisms of cancer occurrence and progression, thereby improving the diagnostics and developing novel therapeutic approaches. Over the past few decades, breakthroughs in gene engineering and editing technologies have led to the fast improvement of chimeric antigen receptor (CAR)-T therapy. CAR-T cell therapies have achieved great success for treating hematological malignancies. However, their application is limited in solid tumors owing to antigen loss and mutation, physical barriers, and an immunosuppressive tumor microenvironment. To overcome the challenges of CAR-T cells, increasing efforts are focused on developing CAR-T to expand its applied ranges. This Special Issue will highlight the latest advances in research on tumorigenesis and cancer progression, as well as the advancements of CAR engineering for solid tumors, which will cover both basic and clinical aspects that advance our understanding of human cancer.

Prof. Dr. Ming Sun
Dr. Xianghua Liu
Dr. Xuefei Shi
Topic Editors